Saturday 17 October 2026 Export CLPT’s income statement to Excel — free account

ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

9.07 0.57 −5.91%

Follow CLPT

Alert me

Market cap: $294.1M
P/E: 0.0×
Fwd P/E: −11.6×
Dividend yield: —
F-score: 4/9
Altman Z: 0.44
Beneish M: −1.74
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.47

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	2	1	—	—	2	3	—	—	—	—

Insider Ownership 10.26%

Capital & Financial Ratios $m

Market Cap 294.06

Revenue 42.28

Net Income (34.57)

Free Cash Flow (31.29)

Net Debt 20.87

Current Ratio 4.74

Debt/Equity 4.66

P/E ratio 0.00

Fwd P/E (11.60)

P/S ratio 6.47

P/B ratio 25.39

Past 5Y EPS Growth —

This Y EPS Growth (45.00%)

Next Y EPS Growth 8.43%

Next Y revenue growth 32.54%

Next 5Y EPS Growth (2.88%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 46.89%

10-year low 10-year high

P/B against its own 10 years 83.51%

10-year low 10-year high

EV/Sales against its own 10 years 51.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack
2017	Powerpack
2016	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	23	20	46	29
Receivables	3	5	7	8
Inventory	8	7	8	9
Other	—	—	—	—
	36	33	64	49

	2023	2024	2025	Q'26
Payables	0	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	2
	7	10	11	10

Compound Annual Growth %

	10y	5y	3y
Sales	23.19%	23.58%	21.62%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	63.79%	(8.76%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	12	11	—	—	—
’25	8	9	9	10	37
’24	8	8	8	8	31
’23	5	6	6	7	24
’22	5	5	5	5	21
’21	4	3	5	4	16
’20	3	2	4	4	13

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(7)	—	—	—
’25	(6)	(3)	(3)	(12)	(24)
’24	(4)	(3)	(1)	(1)	(9)
’23	(6)	(5)	(2)	(1)	(14)
’22	(4)	(5)	(4)	(3)	(16)
’21	(2)	(4)	(3)	(4)	(13)
’20	(2)	(2)	(1)	(2)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	—	—	—
’25	(6)	(3)	(3)	(12)	(24)
’24	(4)	(3)	(1)	(2)	(9)
’23	(6)	(6)	(2)	(1)	(15)
’22	(4)	(5)	(4)	(3)	(17)
’21	(2)	(4)	(3)	(4)	(13)
’20	(3)	(2)	(1)	(2)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.32)	(0.38)	—	—	—
’25	(0.22)	(0.21)	(0.21)	(0.27)	(0.90)
’24	(0.16)	(0.16)	(0.18)	(0.20)	(0.70)
’23	(0.23)	(0.29)	(0.20)	(0.19)	(0.90)
’22	(0.17)	(0.18)	(0.15)	(0.18)	(0.68)
’21	(0.13)	(0.17)	(0.18)	(0.19)	(0.69)
’20	(0.13)	(0.11)	(0.09)	(0.09)	(0.43)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.99	1.76	1.33	1.60	2.86	10.65	7.00	4.05	5.11	9.76	Analyst estimates 2026–2028 Powerpack
	High	20.00	7.40	3.65	5.86	16.49	31.29	16.96	11.00	17.47	30.10
People
People	Employees	33	34	38	49	67	80	108	107	115	172
	Revenue/emp, $m	0.17	0.22	0.19	0.23	0.19	0.20	0.19	0.22	0.27	0.21
Income, $m
Income, $m	Revenue	6	7	7	11	13	16	21	24	31	37
	Gross margin, %	54.03	60.72	66.91	64.86	71.09	68.24	65.84	56.83	60.92	61.38
	EBT	(8)	(7)	(6)	(6)	(7)	(14)	(16)	(22)	(19)	(25)
	EBT margin, %	(140.36)	(97.13)	(83.82)	(49.39)	(52.86)	(88.41)	(79.97)	(92.21)	(60.22)	(68.93)
	Net income	(8)	(7)	(6)	(6)	(7)	(14)	(16)	(22)	(19)	(26)
	Depreciation	1	1	1	1	1	1	1	2	2	2
Per share, $
Per share, $	Revenue	2.09	0.95	0.67	0.85	0.81	0.79	0.85	0.97	1.16	1.31
	Earnings	(2.93)	(0.93)	(0.56)	(0.42)	(0.43)	(0.69)	(0.68)	(0.90)	(0.70)	(0.90)
	Cash flow	(2.11)	(0.77)	(0.42)	(0.22)	(0.49)	(0.61)	(0.67)	(0.56)	(0.33)	(0.84)
	Capex	(0.04)	0.00	(0.01)	(0.01)	(0.03)	(0.01)	(0.05)	(0.04)	(0.01)	(0.02)
	Free cash flow	(2.15)	(0.78)	(0.43)	(0.23)	(0.52)	(0.62)	(0.72)	(0.60)	(0.34)	(0.86)
	Book value	(0.27)	0.75	0.14	0.35	0.15	2.35	1.53	0.86	0.94	0.99
	Shares, m	3	8	11	13	16	21	24	25	27	28
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1.63	2.77	2.33	5.63	19.63	14.27	9.79	6.94	13.24	10.48
	P/B	0.00	3.50	11.35	13.77	105.96	4.77	5.45	7.86	16.37	13.82
	EV/Sales	2.57	2.18	2.66	5.32	19.73	11.56	8.45	6.40	12.92	10.56
	EV/FCF	(2.49)	(2.67)	(4.16)	(19.73)	(30.50)	(14.16)	(10.03)	(10.22)	(40.44)	(15.63)
Cash, $m
Cash, $m	Operating cash flow	(6)	(6)	(5)	(3)	(8)	(13)	(16)	(14)	(9)	(24)
	Capex	0	0	0	0	0	0	(1)	(1)	0	(1)
	Free cash flow	(6)	(6)	(5)	(3)	(8)	(13)	(17)	(15)	(9)	(24)
Balance, $m
Balance, $m	Working capital	3	8	5	7	22	57	44	29	23	53
	Total debt	4	5	3	2	21	10	10	10	—	49
	Net debt	1	(4)	0	(4)	1	(44)	(28)	(13)	(20)	3
	Shareholders’ equity	(1)	6	2	5	2	49	37	21	25	28
Returns, %
Returns, %	ROA	(93.09)	(67.30)	(56.66)	(56.01)	(32.73)	(30.31)	(27.15)	(45.01)	(46.22)	(37.30)
	ROIC	(1,114.66)	(271.78)	(173.49)	(298.16)	(109.26)	(185.09)	(109.86)	(175.75)	(233.37)	(48.45)
	ROE	589.65	(282.59)	(167.95)	(181.73)	(194.80)	(56.33)	(38.37)	(76.09)	(81.24)	(95.64)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CV CapsoVision, Inc.	$343.2M	2.1×	— (loss-making)	+9.89% (above 0%: growing)	n/m	−84.44% (below 0%: shrinking)	51.36%	(208.07%)	Compare
RCEL Avita Medical Inc.	$333.1M	— (loss-making)	— (loss-making)	+17.83% (above 0%: growing)	n/m	+66.52% (above 0%: growing)	81.87%	(28.42%)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
Median of peers	$272.6M	2.9×	—	−1.25%	—	−15.77%	68.23%	(106.15%)

All 149 Medical Devices stocks →

ClearPoint Neuro, Inc. (CLPT) key facts

Strength: ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024.
ClearPoint Neuro, Inc. (CLPT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CLPT traded at $9.07, a market capitalization of $294.1 million.
Return on equity was −95.6% and debt-to-equity 4.66.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.44 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.